A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity

NCT02567851 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Hodgkin Disease

Interventions

DRUG: Brentuximab Vedotin

Sponsor

University of Birmingham

Collaborators

[object Object]
[object Object]